Hetero Research Foundation
Records under this name other than the patents Hetero Research Foundation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 23 patents it holds.
Back to Hetero Research Foundation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,853,430 | Crystalline Hydrochloride Salt of Darunavir Lapsed on the fee record Ended Oct 7, 2026 · High confidence | Lapsed on the fee record | Ended Oct 7, 2026 | High confidence |
| US 10,023,526 | Process for the Preparation of Lomitapide Lapsed on the fee record Ended Jul 17, 2026 · High confidence | Lapsed on the fee record | Ended Jul 17, 2026 | High confidence |
| US 8,779,143 | Crystalline Forms of Maraviroc Phosphate and Process for Maraviroc Amorphous Form Lapsed on the fee record Ended Jul 15, 2026 · High confidence | Lapsed on the fee record | Ended Jul 15, 2026 | High confidence |
| US 8,742,105 | Polymorphs of raltegravir potassium Lapsed on the fee record Ended Jun 3, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 3, 2026 | USPTO record |
| US 8,598,341 | Process for etravirine intermediate and polymorphs of etravirine Lapsed on the fee record Ended Dec 3, 2025 · USPTO record | Lapsed on the fee record | Ended Dec 3, 2025 | USPTO record |
| US 9,783,542 | Process for pralatrexate Lapsed on the fee record Ended Oct 10, 2025 · USPTO record | Lapsed on the fee record | Ended Oct 10, 2025 | USPTO record |
| US 9,273,010 | Process for bendamustine hydrochloride Lapsed on the fee record Ended Mar 1, 2024 · USPTO record | Lapsed on the fee record | Ended Mar 1, 2024 | USPTO record |
| US 9,138,412 | Bioequivalent formulation of efavirenz Lapsed on the fee record Ended Sep 22, 2023 · USPTO record | Lapsed on the fee record | Ended Sep 22, 2023 | USPTO record |
| US 10,370,405 | C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors Formerly held Lapsed on the fee record Ended Aug 6, 2023 · USPTO record | Lapsed on the fee record | Ended Aug 6, 2023 | USPTO record |
| US 8,962,833 | Salts of raltegravir Lapsed on the fee record Ended Feb 24, 2023 · USPTO record | Lapsed on the fee record | Ended Feb 24, 2023 | USPTO record |